Zivo Bioscience - Common Stock, par value $.001 per share (ZIVO)
CUSIP: 98978N101
Q1 2022 13F Holders as of 31 Mar 2022
- Type / Class
- Equity / Common Stock, par value $.001 per share
- Shares outstanding
- 3,908,612
- Total 13F shares
- 82,936
- Share change
- 0
- Total reported value
- $322,000
- Price per share
- $3.89
- Number of holders
- 2
Quarterly Holders Quick Answers
What is CUSIP 98978N101?
CUSIP 98978N101 identifies ZIVO - Zivo Bioscience - Common Stock, par value $.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98978N101:
Top shareholders of ZIVO - Zivo Bioscience - Common Stock, par value $.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
341,680
|
$980,000 | — | 31 Dec 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
—
class O/S missing
|
77,321
|
$221,000 | — | 31 Dec 2021 | |
| Schechter Investment Advisors, LLC |
13F
|
Company |
1.5%
|
56,770
|
$163,000 | — | 31 Dec 2021 | |
| CoreCap Advisors, LLC |
13F
|
Company |
0.67%
|
26,166
|
$75,000 | — | 31 Dec 2021 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
class O/S missing
|
25,483
|
$73,000 | — | 31 Dec 2021 | |
| XTX Topco Ltd |
13F
|
Company |
—
class O/S missing
|
22,976
|
$66,000 | — | 31 Dec 2021 | |
| Ayrton Capital LLC |
13F
|
Company |
—
class O/S missing
|
48,850
|
$46,000 | — | 31 Dec 2021 | |
| Verdence Capital Advisors LLC |
13F
|
Company |
—
mixed-class rows
|
20,000
mixed-class rows
|
$38,000 | — | 31 Dec 2021 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
—
class O/S missing
|
8,313
|
$24,000 | — | 31 Dec 2021 | |
| Warberg Asset Management LLC |
13F
|
Company |
—
class O/S missing
|
19,441
|
$18,000 | — | 31 Dec 2021 | |
| CVI Holdings, LLC |
13F
|
Company |
—
class O/S missing
|
16,108
|
$15,000 | — | 31 Dec 2021 | |
| UBS Group AG |
13F
|
Company |
—
mixed-class rows
|
6,003
mixed-class rows
|
$14,000 | — | 31 Dec 2021 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
—
class O/S missing
|
1,875
|
$5,000 | — | 31 Dec 2021 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
class O/S missing
|
1,219
|
$3,000 | — | 31 Dec 2021 | |
| MORGAN STANLEY |
13F
|
Company |
—
class O/S missing
|
944
|
$3,000 | — | 31 Dec 2021 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
—
class O/S missing
|
626
|
$2,000 | — | 31 Dec 2021 | |
| Andrew A. Dahl |
3/4/5
|
President / CEO, Director |
—
class O/S missing
|
376,000
|
— | — | 21 Oct 2021 |
Institutional Holders of Zivo Bioscience - Common Stock, par value $.001 per share (ZIVO) as of Q1 2022
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2022 vs Q4 2021 Across Filers
| Investor | Q4 2021 Shares | Q1 2022 Shares | Share Diff | Share Chg % | Q4 2021 Value $ | Q1 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.